[CLVS] Clovis Oncology, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 533.24 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 45.35 Change: 0.32 (0.71%)
Ext. hours: Change: 0 (0%)

chart CLVS

Refresh chart

Strongest Trends Summary For CLVS

CLVS is in the medium-term up 146% in 2 months and down -74% below S&P in 1 year. In the long-term down -94% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding38.39 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.11 Price/Cash Per Share
Price/Free Cash Flow-4.47 ROA-27.31% ROE-76.19% ROI
Current Ratio7.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.19 M Cash From Investing Activities-143.03 M Cash From Operating Activities-48.41 M Gross Profit
Net Profit-63.14 M Operating Profit-64.22 M Total Assets704.71 M Total Current Assets441.7 M
Total Current Liabilities55.68 M Total Debt287.5 M Total Liabilities452.12 M Total Revenue
Technical Data
High 52 week32.67 Low 52 week3.12 Last close3.21 Last change2.88%
RSI20.96 Average true range0.29 Beta1.33 Volume1.42 M
Simple moving average 20 days-17.78% Simple moving average 50 days-36.87% Simple moving average 200 days-80.19%
Performance Data
Performance Week1.58% Performance Month-43.19% Performance Quart-73.97% Performance Half-84.87%
Performance Year-87.99% Performance Year-to-date-82.13% Volatility daily3.69% Volatility weekly8.26%
Volatility monthly16.93% Volatility yearly58.65% Relative Volume1318.58% Average Volume3.84 M
New High New Low

News

2020-01-16 09:09:02 | Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

2020-01-15 16:11:09 | Why This Highly Rated Biotech Stock Jumped As High As 26%

2020-01-15 09:27:00 | Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment

2020-01-15 08:00:00 | Clovis Oncology’s Rubraca® rucaparib Granted FDA Priority Review for Advanced Prostate Cancer

2020-01-14 15:12:08 | Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

2020-01-07 07:26:00 | Clovis Oncology Announces Debt Refinancing Transaction

2020-01-07 07:25:00 | Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019

2020-01-02 08:55:01 | Implied Volatility Surging for Clovis CLVS Stock Options

2019-12-29 18:38:06 | Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

2019-12-27 12:08:05 | FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug

2019-12-18 10:31:03 | Corporate News for Dec 18, 2019

2019-12-16 08:30:00 | Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium

2019-12-10 08:35:01 | Implied Volatility Surging for Clovis CLVS Stock Options

2019-12-09 07:18:05 | Cramer Gives His Take On Bank Of America, BlackBerry And More

2019-12-08 15:16:52 | Did Hedge Funds Drop The Ball On Clovis Oncology Inc CLVS ?

2019-12-07 11:31:04 | Clovis CLVS Up 122.5% Since Last Earnings Report: Can It Continue?

2019-12-06 13:41:02 | ESG and Mission-Critical Issues for Director & Officer Liability

2019-12-04 10:41:03 | Immunomedics Resubmits Application for Breast Cancer Drug

2019-12-02 05:41:25 | Introducing Clovis Oncology NASDAQ:CLVS, The Stock That Tanked 76%

2019-11-29 12:15:05 | Biotech Tops in November: Best ETFs & Stocks

2019-11-29 11:01:04 | Clovis Oncology, Inc. CLVS Shares March Higher, Can It Continue?

2019-11-27 09:00:02 | Clovis CLVS Looks Good: Stock Adds 6.3% in Session

2019-11-26 09:00:02 | Clovis CLVS Upgraded to Buy: Here's Why

2019-11-22 12:56:46 | 3 Momentum Stocks To Watch Post-Earnings

2019-11-22 12:50:00 | Three momentum stocks to watch after company earnings reports

2019-11-19 16:54:22 | Teva, Bausch Could Be Next to File for Bankruptcy

2019-11-14 13:00:06 | Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

2019-11-13 04:00:00 | Clovis Oncology Announces Reimbursement for Rubraca® rucaparib Tablets for Women with Relapsed Ovarian Cancer in Italy

2019-11-11 10:29:03 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options

2019-11-08 10:49:16 | Were Hedge Funds Right About Dumping Clovis Oncology Inc CLVS?

2019-11-08 09:32:02 | Clovis CLVS Q3 Earnings & Sales Beat Estimates, Shares Up

2019-11-07 22:11:26 | Edited Transcript of CLVS earnings conference call or presentation 7-Nov-19 1:30pm GMT

2019-11-07 09:25:02 | Clovis Oncology CLVS Reports Q3 Loss, Tops Revenue Estimates

2019-11-07 08:00:00 | Clovis Oncology Announces Third Quarter 2019 Operating Results

2019-11-07 07:18:13 | The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

2019-10-31 10:34:02 | Analysts Estimate Clovis Oncology CLVS to Report a Decline in Earnings: What to Look Out for

2019-10-22 08:30:00 | Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7

2019-10-11 09:19:00 | Clovis Oncology Announces Rubraca®? rucaparib Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

2019-10-09 11:22:03 | Clovis CLVS Shares Drop on Goldman Sachs' Bearish Outlook

2019-10-08 11:08:16 | Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

2019-10-04 10:31:02 | J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

2019-10-02 07:47:40 | Is Clovis Oncology, Inc.'s NASDAQ:CLVS CEO Pay Fair?

2019-09-30 09:00:01 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options

2019-09-29 02:30:00 | Clovis Oncology Highlights Rubraca® rucaparib Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

2019-09-25 11:10:03 | Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More

2019-09-24 14:08:21 | Clovis Oncology Call Volume Spikes After Downgrade

2019-09-24 11:36:03 | Clovis Gains Rights to Pre-Clinical Cancer Program for $12M

2019-09-24 08:58:00 | Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed

2019-09-24 08:12:30 | The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

2019-09-23 04:00:00 | Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals